Monday, September 10, 2012

Cell Therapeutics Gains Momentum (GCI, KSW, CTIC, TITN, GRPN)

Gannett Co., Inc. (NYSE:GCI) shares declined 0.06% to $16.05 in the morning hour after the company announced that it has entered into a partnership with InnerWorkings  to exclusively manage print procurement and print management for non-newspaper print products such as direct mail, marketing collateral, inserts and select publications, among other items.

KSW, Inc. (NASDAQ:KSW) stock soared 22.11% to $4.97 after the company announced that they have entered into a definitive merger agreement. Under the terms of the agreement, a subsidiary of Related Companies will acquire all of the outstanding shares of common stock of KSW for $5.00 per share in cash through a cash tender offer followed by a merger. The transaction is valued in the aggregate at approximately $32.1 million.

Will KSW Continue To Move Up? Find Out Here

Cell Therapeutics Inc (NASDAQ:CTIC) stock gained 5.17% to $2.44. The company’s management will present at the Annual Rodman & Renshaw Global Investment Conference on Tuesday, September 11 at 10:25 a.m. Eastern/ 4:25 p.m. Central European/ 7:25 a.m. Pacific time in the Starlight North room of the Waldorf-Astoria Hotel.

Titan Machinery Inc. (NASDAQ:TITN) shares declined 16.76% to $21.11 in the early hour after the company posted second quarter profit of $5.21 million, or $0.25 a share, as compared with $6.29 million, or $0.30 a share, in the same quarter a year earlier. Revenue jumped 32% to $410 million. Analysts had most recently forecast earnings of $0.43 a share on revenue of $402 million.

Groupon Inc (NASDAQ:GRPN) shares increased 0.23% to $4.28 in the morning hour. The company’s reported that its Chairman Eric Lefkofsky relocated 18.7 million of his firm’s shares to early investors, consultants and advisers. The total of 15.4 million of the shares were transferred from a firm know 600 West Groupon LLC, which is handled by a company owned equally by Lefkofsky and his wife.

No comments:

Post a Comment

Privacy Policy | Legal Disclaimer